AstraZeneca stock: RBC keeps target at GBp 14,500 for AstraZeneca stock

Published on 10/19/2026 at 16:31 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

AstraZeneca reports third-quarter results on October 30, 2026. AstraZeneca stock costs EUR 147.73 on October 19, 2026 at 4:14 p.m. CEST.

Targets and reporting dates

RBC maintained its GBp 14,500 target on October 15, 2026.
AstraZeneca expects to publish third-quarter results on October 30, 2026.
AstraZeneca stock costs EUR 147.73 at Lang & Schwarz on October 19, 2026 at 4:14 p.m. CEST.
The London quotation stood at GBp 12,440 at 3:28 p.m. London time on October 19, 2026.

Bauhaus-Poster mit Formen, Molekülstruktur, DNA-Helix und Schriftzug PHARMA — AstraZeneca plc (ISIN GB0009895292) zählt zu den weltweit größten Unternehmen der forschenden Pharmaindustrie und Biotechnologie, Illustration mit AI erstellt.

RBC Capital Markets maintained its Outperform rating and GBp 14,500 target for AstraZeneca on October 15, 2026, according to Yahoo Finance. Compared with the London quotation of GBp 12,440 at 3:28 p.m. London time on October 19, 2026, the target stands 16.56 percent above the share price. AstraZeneca stock was trading at EUR 147.73 at Lang & Schwarz on October 19, 2026 at 4:14 p.m. CEST.

RBC target leaves room for results

RBC expects third-quarter revenue of USD 16.3 billion, 1.8 percent above its USD 16.0 billion consensus estimate, and core earnings per share of USD 2.61, 0.8 percent above the USD 2.59 consensus. The figures are forecasts for the third quarter, not reported results. The same Yahoo Finance report says RBC expects oncology revenue of USD 7.1 billion, while Tagrisso sales are forecast at USD 2.1 billion.

Stock sits below its yearly high

The London share price was GBp 12,440 on October 19, 2026, with a session high of GBp 12,464, a low of GBp 12,298 and volume of 532,118 shares. Its 52-week range was GBp 9,892 to GBp 15,732, placing the share 20.92 percent below the high and 25.76 percent above the low. The London price was down 0.05 percent from its previous close of GBp 12,446.

Valuation and upcoming dates

AstraZeneca had a market capitalization of GBP 192.9 billion, a price-to-earnings ratio of 24.80 and a dividend yield of 2.00 percent on October 19, 2026. Its next scheduled reporting date is October 30, 2026, when the company is due to publish nine-month and third-quarter 2026 results. The date appears on AstraZeneca's investor relations page.

Calendar gives the market a marker

The October 30 report is the next scheduled company event, while the investor meeting at the ESMO Congress is set for October 26, 2026. The investor relations calendar also lists a November 2, 2026 roadshow in London. For investors, the dated calendar matters because RBC's target case is tied to the company delivering the forecasts outlined ahead of the quarterly release.

Price and investor perspective

The combination of a GBp 14,500 target and an October 30 results date gives the stock a defined near-term reference point. The London share price remains below its GBp 15,732 yearly high, while the current euro quotation was EUR 147.73 at Lang & Schwarz on October 19, 2026 at 4:14 p.m. CEST. The further course of trading is shown by the continuously updated real-time quote of AstraZeneca stock.